Based on these molecular features, several clinical trials in NF-2 wild type meningiomas, including targeted therapy for actionable mutations in PIK3CA, SMO, and AKT1 are ongoing (NCT02523014) [3, 4]. The gene discussed is AKT1; the disease is meningioma.